Showing 2101-2110 of 5062 results for "".
Bio-Logistics: Steps for Improving Access to Biologic Therapy
https://practicaldermatology.com/topics/practice-management/bio-logistics-steps-for-improving-access-to-biologic-therapy/21192/Dealing with insurance companies can be a burden for many practices, but here are some steps to help expedite the process.New Products
https://practicaldermatology.com/topics/practice-management/new-products/21198/A Case of Deductible Reasoning and Social Media Extortion
https://practicaldermatology.com/topics/practice-management/a-case-of-deductible-reasoning-and-social-media-extortion/21201/6 Tips to Stay Updated with Social Media Trends
https://practicaldermatology.com/topics/practice-management/6-tips-to-stay-updated-with-social-media-trends/21204/Staying on top of social media trends allows physicians to maintain a marketing edge.Recent Developments
https://practicaldermatology.com/columns/recent-developments/news/21265/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21300/Reduce Burnout
https://practicaldermatology.com/topics/practice-management/reduce-burnout/21320/Riding the teeter-totter of a healthy work-life balance.Home Devices: Do They Actually Work?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/home-devices-do-they-actually-work/21334/Although home devices may appeal to patients due to their convenience, often they fall short when it comes to sound science and optimal outcomes.I Object! Questions Facing Physicians' Rights to Dispute Sunshine Data
https://practicaldermatology.com/topics/general-topics/i-object-questions-facing-physicians-rights-to-dispute-sunshine-data/21351/Will your practice be prepared when CMS posts Sunshine disclosures later this year?DermwireTV — Valeant Ups Allergan Bid, Nestle Buys Injectables, and Allergan Makes Its Case
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-valeant-ups-allergan-bid-nestle-buys-injectables-and-allergan-makes-its-case/19128/BREAKING NEWS: Valeant has increased its offer for Allergan to $72 per share. Read more. Valeant sells the rights to its aesthetic injectables to Nestle, while Allergan touts physician support and challenges Valeant's business model. In this week's edition of DermWireTV, learn about Valeant's lates